BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND SPEN, Q96T58, 23013, ENSG00000065526, SHARP, RP1-134O19_1, MINT, KIAA0929 AND Prognosis
3230 results:

  • 1. The role of proinflammatory cytokines and CXC chemokines (CXCL1-CXCL16) in the progression of prostate cancer: insights on their therapeutic management.
    Ullah A; Jiao W; Shen B
    Cell Mol Biol Lett; 2024 May; 29(1):73. PubMed ID: 38745115
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. CYP7B1 as a Biomarker for prostate cancer Risk and Progression: Metabolic and Oncogenic Signatures (Diagnostic Immunohistochemistry Analysis by Tissue Microarray in prostate cancer Patients-Diamond Study).
    Russo GI; Durukan E; Asmundo MG; Lo Giudice A; Salzano S; Cimino S; Rescifina A; Fode M; Abdelhameed AS; Caltabiano R; Broggi G
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731981
    [TBL] [Abstract] [Full Text] [Related]  

  • 3.
    Fan Y; Ge Y; Niu K; Li Y; Qi LW; Zhu H; Ma G
    Front Immunol; 2024; 15():1364329. PubMed ID: 38698844
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
    Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
    BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification and Quantification of Radiotherapy-related Protein Expression in cancer Tissues Using the Qupath Software and Prediction of Treatment Response.
    Hasegawa T; Someya M; Tsuchiya T; Kitagawa M; Fukushima Y; Gocho T; Mafune S; Okuda R; Kaguchi J; Ohguro A; Kamiyama R; Ashina A; Toshima Y; Hirohashi Y; Torigoe T; Sakata KI
    In Vivo; 2024; 38(3):1470-1476. PubMed ID: 38688633
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Role of antihypertensive medicines in prostate cancer: a systematic review.
    Iheanacho CO; Enechukwu OH
    BMC Cancer; 2024 Apr; 24(1):542. PubMed ID: 38684963
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer.
    Scheipner L; Baudo A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Carmignani L; De Cobelli O; Mischinger J; Ahyai S; Karakiewicz PI
    World J Urol; 2024 Apr; 42(1):269. PubMed ID: 38679642
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Transcription Factors in prostate cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.
    Silva KCS; Tambwe N; Mahfouz DH; Wium M; Cacciatore S; Paccez JD; Zerbini LF
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674385
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Comprehensiveness cuproptosis related genes study for prognosis and medication sensitiveness across cancers, and validation in prostate cancer.
    Yang L; Tang Y; Zhang Y; Wang Y; Jiang P; Liu F; Feng N
    Sci Rep; 2024 Apr; 14(1):9570. PubMed ID: 38671021
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Parathyroid hormone related-protein (PTHrP) in tissues with poor prognosis in prostate cancer patients.
    Zhao Y; Lu SM; Zhong B; Wang GC; Jia RP; Wang Q; Long JH
    Medicine (Baltimore); 2024 Apr; 103(17):e37934. PubMed ID: 38669432
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
    Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
    Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Bioinformatics-based analysis of the effect of general Transcription Factor IIH on prognosis of prostate cancer].
    Li JC; Zhu XJ; Ye JH; Tan ZH; Cai SH; Deng YL; Chen J; Tian WC; Luo DH; Zhong WD
    Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(16):1410-1417. PubMed ID: 38644292
    [No Abstract]    [Full Text] [Related]  

  • 13. AAT resistance-related AC007405.2 and AL354989.1 as novel diagnostic and prognostic markers in prostate cancer.
    Deng Y; Zhang C; Yu H; Chen G; Peng X; Li Y; Feng Z; Shi W; Bai X; Gou X; Liu N
    Aging (Albany NY); 2024 Apr; 16(8):7249-7266. PubMed ID: 38643469
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study.
    Cheng Y; Wu L; Xin J; Ben S; Chen S; Li H; Zhao L; Wang M; Cheng G; Du M
    J Transl Med; 2024 Apr; 22(1):366. PubMed ID: 38632662
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Excess weight, weight gain, and prostate cancer risk and prognosis: the PROCA-life study.
    Støyten M; Knutsen T; Stikbakke E; Agledahl I; Wilsgaard T; Eggen AE; Richardsen E; Giovannucci E; Thune I; Haugnes HS
    Acta Oncol; 2024 Apr; 63():154-163. PubMed ID: 38591351
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Risk factor analysis and nomogram construction in patients with distant metastatic prostate cancer at different PSA levels: a study based on the SEER database.
    Li HD; Fan SQ; Qin F; Zhao ST; Kong SP; Ma JG
    Eur Rev Med Pharmacol Sci; 2024 Mar; 28(6):2372-2386. PubMed ID: 38567600
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Primary mucinous adenocarcinoma of the urethra: A contemporary clinicopathologic analysis of 17 patients.
    Alrohaibani A; Osunkoya AO
    Pathol Res Pract; 2024 Apr; 256():155273. PubMed ID: 38565023
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
    Li L; Chen D; Chen X; Zhu J; Bao W; Li C; Miao F; Feng R
    PeerJ; 2024; 12():e16850. PubMed ID: 38562999
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
    Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
    Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 162.